FDA-cleared profile

breastscape v1.0

Olea Medical · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Visualization, analysis, reporting, lesion measurement, kinetic assessment, and MR-guided breast interventional planning; when interpreted by a skilled physician, information may support screening, diagnosis, and intervention planning, but patient management must not rely solely on the results.

Clinical role
Breast MRI visualization, semi-automatic lesion segmentation and measurement, kinetic analysis and reporting, follow-up review, and MR-guided interventional planning.
Images and patients
Mammography/DBT · Breast lesions and breast morphological landmarks including nipple, chest, and skin borders.
Key limitation
Keep in mind: breastscape V1.0 is not intended for primary interpretation of digital mammography. Lossy-compressed mammographic images and digitized film-screen images must not be used for primary interpretation. A skilled physician must interpret the information, and patient-management decisions must not be based solely on the results.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Visualization, analysis, reporting, lesion measurement, kinetic assessment, and MR-guided breast interventional planning; when interpreted by a skilled physician, information may support screening, diagnosis, and intervention planning, but patient management must not rely solely on the results.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast lesions and breast morphological landmarks including nipple, chest, and skin borders. Input: DCE-MRI breast image series in DICOM format accessed through Olea Sphere V3.0, with mammography and ultrasound series available for display-only viewing.
  • Who uses it?Intended users: Trained breast imaging physicians and trained MRI technologists.
  • What does the software produce?Output: Registered MR viewing, subtractions, kinetic curves and semi-quantitative maps, semi-automatic lesion segmentation, lesion volume and 2D/3D diameter, distances to nipple, chest, and skin, BI-RADS annotations and breast-sector localization, follow-up layouts, and BreastLoc outputs for needle block position, insertion point, introducer depth, and insertion-path display.
  • What is its most important limitation?Key limitation: breastscape V1.0 is not intended for primary interpretation of digital mammography. Lossy-compressed mammographic images and digitized film-screen images must not be used for primary interpretation. A skilled physician must interpret the information, and patient-management decisions must not be based solely on the results.

Clinical takeaway. Clinical role: Visualization, analysis, reporting, lesion measurement, kinetic assessment, and MR-guided breast interventional planning; when interpreted by a skilled physician, information may support screening, diagnosis, and intervention planning, but patient management must not rely solely on the results.

Evidence takeaway. Evidence from the reviewed source record: Olea Medical reports extensive internal verification and validation covering product risk assessment, software-module verification, and software validation for the Olea Sphere V3.0 system. The packet also references a pivotal clinical study and additional comparisons with MultiView MR Breast for BreastLoc, direct manual measurements for BreastApp metrics and maps, and validation of reporting, follow-up, mammography loading, and visualization; no numeric sensitivity, specificity, AUC, Dice, or reader-delta endpoint is reported in the packet.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Visualization, analysis, reporting, lesion measurement, kinetic assessment, and MR-guided breast interventional planning; when interpreted by a skilled physician, information may support screening, diagnosis, and intervention planning, but patient management must not rely solely on the results.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Breast MRI visualization, semi-automatic lesion segmentation and measurement, kinetic analysis and reporting, follow-up review, and MR-guided interventional planning.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
DCE-MRI breast image series in DICOM format accessed through Olea Sphere V3.0, with mammography and ultrasound series available for display-only viewing.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
Registered MR viewing, subtractions, kinetic curves and semi-quantitative maps, semi-automatic lesion segmentation, lesion volume and 2D/3D diameter, distances to nipple, chest, and skin, BI-RADS annotations and breast-sector localization, follow-up layouts, and BreastLoc outputs for needle block position, insertion point, introducer depth, and insertion-path display.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Hospitals, imaging centers, and radiologist reading practices.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Trained breast imaging physicians and trained MRI technologists.
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
breastscape V1.0 is not intended for primary interpretation of digital mammography. Lossy-compressed mammographic images and digitized film-screen images must not be used for primary interpretation. A skilled physician must interpret the information, and patient-management decisions must not be based solely on the results.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
Olea Medical reports extensive internal verification and validation covering product risk assessment, software-module verification, and software validation for the Olea Sphere V3.0 system. The packet also references a pivotal clinical study and additional comparisons with MultiView MR Breast for BreastLoc, direct manual measurements for BreastApp metrics and maps, and validation of reporting, follow-up, mammography loading, and visualization; no numeric sensitivity, specificity, AUC, Dice, or reader-delta endpoint is reported in the packet.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Olea Medical reports extensive internal verification and validation covering product risk assessment, software-module verification, and software validation for the Olea Sphere V3.0 system. The packet also references a pivotal clinical study and additional comparisons with MultiView MR Breast for BreastLoc, direct manual measurements for BreastApp metrics and maps, and validation of reporting, follow-up, mammography loading, and visualization; no numeric sensitivity, specificity, AUC, Dice, or reader-delta endpoint is reported in the packet.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

breastscape v1.0 regulatory performance study summary

  • DesignUnspecified
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K211431
  • IndependenceIndependence not established

K211431

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K211431. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DCE-MRI breast image series in DICOM format accessed through Olea Sphere V3.0, with mammography and ultrasound series available for display-only viewing.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K211431: breastscape v1.0

  2. Routing

    Source context, not route validation: The device is an optional PACS module that requires the cleared Olea Sphere V3.0 PACS viewer (K152602), its data and license-management services, and operational use of that package. It accesses MR image series in DICOM format through Olea Sphere V3.0; a specific local PACS or RIS interface beyond that dependency is not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K211431: breastscape v1.0

  3. AI processing

    Source context, not route validation: The exact FDA package describes breastscape V1.0 as an optional PACS software module for use with the Olea Sphere V3.0 software package, whose execution requires Olea Sphere V3.0 and its data and license management services to be started and in operational use. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "breastscape V1.0 is an optional PACS software module intended for use with the cleared Olea Sphere V3.0 software package (K152602)." … "The application execution requires Olea Sphere V3.0 with its components (data and license management services) to be started and in operational use.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K211431: breastscape v1.0

  4. Returned objects

    Source context, not route validation: Registered MR viewing, subtractions, kinetic curves and semi-quantitative maps, semi-automatic lesion segmentation, lesion volume and 2D/3D diameter, distances to nipple, chest, and skin, BI-RADS annotations and breast-sector localization, follow-up layouts, and BreastLoc outputs for needle block position, insertion point, introducer depth, and insertion-path display.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K211431: breastscape v1.0

  5. Viewer/worklist/report

    Unresolved route: Registered MR viewing, subtractions, kinetic curves and semi-quantitative maps, semi-automatic lesion segmentation, lesion volume and 2D/3D diameter, distances to nipple, chest, and skin, BI-RADS annotations and breast-sector localization, follow-up layouts, and BreastLoc outputs for needle block position, insertion point, introducer depth, and insertion-path display.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K211431: breastscape v1.0

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes breastscape V1.0 as an optional PACS software module for use with the Olea Sphere V3.0 software package, whose execution requires Olea Sphere V3.0 and its data and license management services to be started and in operational use. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "breastscape V1.0 is an optional PACS software module intended for use with the cleared Olea Sphere V3.0 software package (K152602)." … "The application execution requires Olea Sphere V3.0 with its components (data and license management services) to be started and in operational use.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The device is an optional PACS module that requires the cleared Olea Sphere V3.0 PACS viewer (K152602), its data and license-management services, and operational use of that package. It accesses MR image series in DICOM format through Olea Sphere V3.0; a specific local PACS or RIS interface beyond that dependency is not established.
  • Exact FDA submission
  • Checked 2026-09-09

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for breastscape v1.0; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K211431
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Breast lesions and breast morphological landmarks including nipple, chest, and skin borders.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2021-08-02
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K211431 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K211431: breastscape v1.0

    U.S. Food and Drug Administration - Published 2021-08-02 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. breastscape v1.0 model card (K211431)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K211431

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K211431 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K250754

cmAngio® (V1.6)

CureMetrix, Inc.

Authorized purpose: cmAngio (V1.6) processes screening mammograms to aid a qualified interpreting physician in the manual process of identifying breast arterial calcification. It detects the presence or absence of breast arterial calcifications at the study and breast level in full-field digital mammography and digital breast tomosynthesis screening mammograms and marks BAC segments on image thumbnails for localization.

Modality
Mammography/DBT
Anatomy
Female breasts; breast arterial calcification
Decision
2025-04-10
FDA-cleared K232367

cmAngio® V1.0

CureMetrix, Inc.

Authorized purpose: cmAngio processes screening FFDM and DBT mammograms to detect presence or absence of breast arterial calcifications at study and breast level and mark segments for qualified interpreting-physician review; it is not primary breast-cancer interpretation or a standalone diagnostic or treatment decision tool.

Modality
Mammography/DBT
Anatomy
Breast; breast arterial calcifications
Decision
2023-10-05
FDA-cleared K163623

Quantra

HOLOGIC, INC.

Authorized purpose: Quantra 2.2 analyzes digital breast X-ray images and categorizes breast density to provide additional information for a radiologist's assessment.

Modality
Mammography/DBT
Anatomy
Breast; mammographic breast-density composition
Decision
2017-10-20
FDA-cleared K142037

QUANTRA

HOLOGIC, INC.

Authorized purpose: Quantra version 2.1 calculates volumetric and area breast-density measures and density categories from supported digital mammography images as an adjunct, not a diagnostic result.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2014-10-10

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history